Ahanchian, 60 patient probiotics prophylaxis RCT: 73% fewer symptomatic cases [p=0.35] and 85% fewer cases [p=0.24] https://c19p.org/ahanchian
copied to clipboard
Synbiotic for Prevention of SARS-Cov2 Infection in High Risk Hospital Staffs: A Randomized Controlled Trial
et al., Open Journal of Nursing, doi:10.4236/ojn.2021.115025
Small RCT 60 healthcare workers in Iran, showing lower cases with treatment but without statistical significance. Once daily oral synbiotic capsule (Lactocare®) containing 1 billion CFU L. (Lactobacillus) casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, Bifidobacterium infantis, L. bulgaricus, and Fructooligosacharide. IRCT-20101020004976N6.The immune effects of probiotics are strain-specific.
|
respiratory symptoms, 73.3% lower, RR 0.27, p = 0.35, treatment 1 of 29 (3.4%), control 4 of 31 (12.9%), NNT 11.
|
|
risk of case, 85.3% lower, RR 0.15, p = 0.24, treatment 0 of 29 (0.0%), control 3 of 31 (9.7%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ahanchian et al., 31 May 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 14 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.